Cancer drugmaker Endocyte raises $75 million in IPO
Endocyte Inc., a developer of drugs for ovarian and lung tumors, raised $75 million in its initial public offering after cutting the price twice this week for a total reduction of as much as 60 percent.
Louisville, Colorado-based GlobeImmune, the developer of biopharmaceuticals aimed at treating cancer and infectious diseases, filed for an IPO Tuesday, saying it is looking to raise up to $69M on the NASDAQ Global Market.